ABSTRACT
The dose of direct oral anticoagulants (DOACs) must be determined based on package insert recommendations. There are reports on the rate of inappropriate DOAC dose usage defined as a dose deviating from the approved dose in the package insert but no reports on factors that led to such deviations. Thus, patients who were admitted to the Suzuka Kaisei Hospital between 1 April 2016 and 31 March 2017 were chosen as subjects. Moreover, the factors that during hospitalization led to dose deviation from the package-insert DOAC dose were retrospectively examined. The characteristics of patients administered doses deviating from the package insert were compared with those of patients in the appropriate-dose group. The finding was that the proportion concomitantly administered antiplatelet agents was higher in the underdose group. In contrast, deviations from the recommended dose did not occur when DOACs were combined with CYP3A4 inhibitors or P-glycoprotein (P-gp) inhibitors. It was suggested that increase in the risk of hemorrhage by antiplatelet agents in combination with oral anticoagulants could explain deviations from the stipulated DOAC dose. In addition, a higher proportion of patients in the overdose group showed depressed Ccr, and gastrointestinal bleeding. In future, it will be necessary to propose principle-based dose changes for patients administered doses deviating from the package insert. If an underdose is administered, it is important to make a dose change that takes the concomitant drugs into consideration.
Subject(s)
Anticoagulants/supply & distribution , Drug Utilization/statistics & numerical data , Hospitalization/statistics & numerical data , Inappropriate Prescribing/statistics & numerical data , Surveys and Questionnaires , ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Administration, Oral , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Cytochrome P-450 CYP3A Inhibitors/administration & dosage , Dosage Forms , Drug Therapy, Combination/adverse effects , Hemorrhage/chemically induced , Hemorrhage/prevention & control , Humans , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Product Labeling , Retrospective Studies , RiskABSTRACT
With the exponential surge in patients with coronavirus disease 2019 (COVID-19) worldwide, the resources needed to provide continuous kidney replacement therapy (CKRT) for patients with acute kidney injury or kidney failure may be threatened. This article summarizes subsisting strategies that can be implemented immediately. Pre-emptive weekly multicenter projections of CKRT demand based on evolving COVID-19 epidemiology and routine workload should be made. Corresponding consumables should be quantified and acquired, with diversification of sources from multiple vendors. Supply procurement should be stepped up accordingly so that a several-week stock is amassed, with administrative oversight to prevent disproportionate hoarding by institutions. Consumption of CKRT resources can be made more efficient by optimizing circuit anticoagulation to preserve filters, extending use of each vascular access, lowering blood flows to reduce citrate consumption, moderating the CKRT intensity to conserve fluids, or running accelerated KRT at higher clearance to treat more patients per machine. If logistically feasible, earlier transition to intermittent hemodialysis with online-generated dialysate, or urgent peritoneal dialysis in selected patients, may help reduce CKRT dependency. These measures, coupled to multicenter collaboration and a corresponding increase in trained medical and nursing staffing levels, may avoid downstream rationing of care and save lives during the peak of the pandemic.
Subject(s)
Betacoronavirus , Continuous Renal Replacement Therapy/trends , Coronavirus Infections/therapy , Health Services Needs and Demand/trends , Pandemics , Pneumonia, Viral/therapy , Acute Kidney Injury/epidemiology , Acute Kidney Injury/therapy , Anticoagulants/administration & dosage , Anticoagulants/supply & distribution , COVID-19 , Continuous Renal Replacement Therapy/instrumentation , Coronavirus Infections/epidemiology , Dialysis Solutions/administration & dosage , Dialysis Solutions/supply & distribution , Humans , Pneumonia, Viral/epidemiology , Renal Insufficiency/epidemiology , Renal Insufficiency/therapy , SARS-CoV-2Subject(s)
Betacoronavirus , Cardiovascular Agents/therapeutic use , Coronavirus Infections , Delivery of Health Care , Evidence-Based Pharmacy Practice , Pandemics , Pneumonia, Viral , Stroke/drug therapy , Anticoagulants/supply & distribution , Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , COVID-19 , Cardiovascular Agents/supply & distribution , Coronavirus Infections/complications , Drug Monitoring , Evidence-Based Pharmacy Practice/methods , Evidence-Based Pharmacy Practice/organization & administration , Humans , Medication Adherence , Medication Systems/organization & administration , Pneumonia, Viral/complications , Quarantine , Recurrence , SARS-CoV-2 , Secondary Prevention , Stroke/complications , Stroke/mortalityABSTRACT
OBJECTIVE: To conduct a survey of diagnostic facility and therapeutic capability of Pulmonary thromboembolism (PE) in 90 hospitals throughout China. METHOD: It was a cross-sectional study among the participating hospitals of the National Key Research & Development Program of China-the Precision Research of Standardized Management and Application of Pulmonary Thromboembolism to obtain the equipment and application of radiological facility to diagnose PE, laboratory tests for thrombophilia, coagulation function and the availability of anticoagulants and thrombolysis agents. RESULTS: CT pulmonary arteriography is capable in all 90 hospitals, 71.11% of the hospitals could perform ventilation/perfusion scintigraphy, 24.44% of the hospitals do not routinely perform right heart evaluation by echocardiography. Protein C and protein S activity can be detected in half of the hospitals and warfarin pharmacogenomics tests can be conducted in 40 hospitals. Immune turbidimetry was used as the detection method of D-dimer in 72.37% hospitals. About 81.11% of participating hospitals were equipped with new novel oral anticoagulants, all of which were equipped with Rivaroxaban. CONCLUSION: The hospitals are capable for standardized diagnosis and management PE, while the capability of precise stratification, coagulation function tests, thrombophilia screening and pharmacogenomics requires further improvement.
Subject(s)
Hospital Bed Capacity/statistics & numerical data , Patient Care Management/statistics & numerical data , Pulmonary Embolism/diagnosis , Pulmonary Embolism/therapy , Angiography/statistics & numerical data , Anticoagulants/supply & distribution , Anticoagulants/therapeutic use , Blood Coagulation Tests/methods , Blood Coagulation Tests/statistics & numerical data , China/epidemiology , Cross-Sectional Studies , Echocardiography/statistics & numerical data , Factor Xa Inhibitors/supply & distribution , Factor Xa Inhibitors/therapeutic use , Fibrin Fibrinogen Degradation Products/analysis , Fibrinolytic Agents/supply & distribution , Fibrinolytic Agents/therapeutic use , Hospitals/statistics & numerical data , Humans , Nephelometry and Turbidimetry/statistics & numerical data , Pharmacogenetics/statistics & numerical data , Pulmonary Embolism/epidemiology , Rivaroxaban/supply & distribution , Rivaroxaban/therapeutic use , Surveys and Questionnaires/statistics & numerical data , Thrombophilia/blood , Ventilation-Perfusion Scan/statistics & numerical data , Warfarin/metabolismABSTRACT
Most of the unfractionated and low-molecular-weight heparins available worldwide are produced by Chinese companies from porcine mucosa. China is the world's largest producer of pork and thus has plenty of raw material to produce heparins. However, the deadly African Swine Fever (ASF) outbreaks afflicting China since August 2018 may cause extensive losses to the pig herd, with serious consequences for the global supply of heparins. In 2008, a sudden shortage of heparin's raw material resulting from a viral disease in Chinese pigs prompted adulterations responsible for 80 deaths and hundreds of adverse events. This incident revealed the fragility of such a supply chain, which is mostly based on raw material from a single animal from a single country. A worldwide introduction of bovine mucosa heparins manufactured in different countries certainly is a feasible way to mitigate eventual shortages of these life-saving anticoagulants caused by local veterinary problems such as the ASF threatening China now.
Subject(s)
African Swine Fever Virus/pathogenicity , African Swine Fever/virology , Anticoagulants/supply & distribution , Disease Outbreaks/veterinary , Heparin/supply & distribution , Intestinal Mucosa/metabolism , Animals , Anticoagulants/isolation & purification , China , Heparin/isolation & purification , Sus scrofa , SwineABSTRACT
There is currently a lack of consensus on which anticoagulant therapy contraindications should be considered "absolute" and which should be considered "relative". Guidelines do not clearly identify absolute and relative contraindications to anticoagulant therapy. Recent guidelines on AF of the European Society of Cardiology underline the relevance of several factors and their use in scores, leaving anyway space to the clinical judgment of the physician. A high bleeding risk score should generally not result per se in a contraindication to anticoagulant therapy. Rather, bleeding risk factors should be identified and treatable factors corrected. A combined use of a more hierarchical classification of the different bleeding risk factors and the risk scores probably represents the best approach to maximize the benefit of anticoagulant therapy in various clinical settings.
Subject(s)
Anticoagulants/supply & distribution , Atrial Fibrillation/drug therapy , Cardiology/organization & administration , Contraindications , Administration, Oral , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Europe/epidemiology , Female , Guidelines as Topic , Hemorrhage/classification , Hemorrhage/etiology , Humans , International Normalized Ratio/methods , Male , Pregnancy , Risk Factors , Stroke/etiology , Stroke/mortality , Venous Thromboembolism/etiology , Venous Thromboembolism/mortalityABSTRACT
OBJECTIVE: Unfractionated heparin is a mixture of glycosaminoglycans with different pharmacologic and pharmacokinetic properties. The literature suggests that blood loss after cardiac surgery is related to both elevated postoperative heparin concentrations and the potency of different heparin brands. DESIGN: An audit of the observed increase in the incidence of cardiac surgery-related bleeding after change in heparin supplier. Patient characteristics were compared between groups before and after a change in heparin brands. SETTING: Tertiary cardiothoracic center. PARTICIPANTS: All patients undergoing cardiac surgery between August 1, 2011, and April 30, 2012. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Two hundred eighty patients underwent surgery before a change in heparin brands and 216 after a change. Their preoperative and intraoperative characteristics were similar. Postoperative chest tube drainages and blood transfusions were significantly greater after the change in heparin brands (postoperative chest drainage 476.8 ± 393.1 v 344.8 ± 323.2 mL/6 h and 1,062.2 ± 738.8 v 841.8 ± 567.4 mL/24 h, respectively; both p < 0.001) despite the administration of larger amounts of protamine, fresh frozen plasma/platelet transfusions, and cryoprecipitate. Heparin recirculation within 24 hours of bypass was noted in about 70% of the samples tested using either anti-factor X activity or the thromboelastography ratio between nonheparinase R and heparinase-modified R and was not associated with the heparin brand. The likelihood ratio chi-square test for nested models identified an added predictive value of the heparin brand when included as a predictor of bleeding (chest drainage >800 mL/6 h) in a model comprising recirculation, assessed using either an elevated anti-factor X activity or ratio between nonheparinase R and heparinase-modified R. CONCLUSION: It is likely that the observed increase in postoperative bleeding was related to the pharmacologic properties of the new heparin brand rather than a higher incidence of heparin recirculation.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Drug Substitution/adverse effects , Heparin/adverse effects , Heparin/supply & distribution , Postoperative Hemorrhage/chemically induced , Postoperative Hemorrhage/diagnosis , Aged , Anticoagulants/adverse effects , Anticoagulants/supply & distribution , Cardiac Surgical Procedures/trends , Cohort Studies , Drug Substitution/trends , Female , Follow-Up Studies , Humans , Male , Middle Aged , Postoperative Hemorrhage/epidemiology , Retrospective StudiesABSTRACT
OBJECTIVE: Gender is an important feature in the management of atrial fibrillation (AF). This study investigated gender-related differences in patients with AF in Turkey. METHODS: As a part of RAMSES (ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in Turkey, NCT02344901) study, information of the patients with AF who successively applied to the hospital was analyzed. This cross-sectional, multicenter, nationwide observational study enrolled 6264 non-valvular AF (NVAF) outpatients (55.9% women) from Turkey. RESULTS: Compared with men, women with NVAF were older (71 years [range: 65-78 years] vs. 70 years [range: 62-77 years]; p<0.001), had lower frequency of coronary artery disease (22.0% vs. 38.3%; p<0.001) and congestive heart failure (18.2% vs. 27.2%; p<0.001). Women had higher median CHA2DS2-VASc score (4 [range: 3-5] vs. 3 [range: 2-4]; p<0.001), but similar HAS-BLED score (2 [range: 1-2] vs. 2 [range: 1-2]; p=0.141) when compared with men. Anticoagulant therapy use was higher in women (74.5% vs. 69.9%; p<0.001). Analysis of anticoagulation therapy use revealed that 68.5% of men and 61.6% of women (p=0.204) who had low risk for stroke (CHA2DS2-VASc score: 0 [male], 1 [female]) received anticoagulation therapy, and 30.5% of the men. Meanwhile, 25.3% of the women (p<0.001) with high risk for stroke (CHA2DS2-VASc score: ≥1 [male], ≥2 [female]) had not received any anticogulant therapy. CONCLUSION: Although women with NVAF receive better treatment than men, anticoagulation therapy is suboptimal in large proportion of men and women, with underuse in high-risk patients and overuse in low-risk patients. There is an urgent need to improve optimization of anticoagulation in patients with NVAF.
Subject(s)
Anticoagulants/supply & distribution , Atrial Fibrillation/epidemiology , Brain Ischemia/prevention & control , Practice Patterns, Physicians' , Age Factors , Aged , Atrial Fibrillation/etiology , Atrial Fibrillation/pathology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Risk Factors , Severity of Illness Index , Sex Factors , Turkey/epidemiologyABSTRACT
OBJECTIVE: New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). In this study, we aimed to evaluate the current patterns of NOACs treatment in Turkey. Moreover, demographic and clinical parameters and bleeding and/or embolic events under NOACs treatment were analyzed. METHODS: The New Oral Anticoagulants-TURKey (NOAC-TURK) study was designed as a multicenter cross-sectional study. A total of 2,862 patients from 21 different centers of Turkey under the treatment of NOACs for at least three months were included in this study. Demographic, clinical, and laboratory characteristics of study participants with their medications used were obtained through the NOAC-TURK survey database. Additional necessary medical records were obtained from electronic health records of participating centers. RESULTS: Of the 2. 862 patients, 1.131 (39.5%) were male and the mean age was 70.3±10.2 years. Hypertension was found as the most frequent comorbidity (81%). The most common indication for NOACs was permanent atrial fibrillation (83.3%). NOACs were mainly preferred because of inadequate therapeutic range or overdose during warfarin usage. The most frequent complication was bleeding (n=217, 7.6%), and major bleeding was observed in 1.1% of the patients. Embolic events were observed in 37 patients (1.3%). Rivaroxaban and dabigatran were both more preferred than apixaban. Almost half of the patients (47.6%) were using lower doses of NOACs, which is definitely much more than expected. CONCLUSION: The NOAC-TURK study showed an important overview of the current NOACs treatment regimens in Turkey. Although embolic and bleeding complications were lower than or similar to previous studies, increased utilization of low-dose NOACs in this study should be considered carefully. According to the results of this study, NOACs treatment should be guided through CHA2DS2-VASc and HASBLED scores to ensure more benefit and less adverse effects in NVAF patients.
Subject(s)
Anticoagulants/supply & distribution , Atrial Fibrillation/drug therapy , Administration, Oral , Aged , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Cross-Sectional Studies , Databases, Factual , Female , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , Incidence , Male , Risk Assessment , Turkey/epidemiologyABSTRACT
OBJECTIVES: This study aims to determine the pre- and postoperative approaches of orthopedic surgeons and operative room environment facilities in total knee arthroplasty (TKA) and total hip arthroplasty (THA) in Turkey. MATERIALS AND METHODS: Data for this study were collected through a questionnaire completed by 234 physicians randomly identified from the database of Turkish Society of Orthopedics and Traumatology. The questionnaire comprised 19 questions investigating the operative room environment, demographic characteristics of surgeons, laboratory and radiologic analyses required by surgeons in pre- and postoperative patient evaluation, and management of postoperative complications. RESULTS: In Turkey, 48% of the operating rooms where TKA and THA are performed lack laminar airflow, while 35% lack HEPA filters. Only 20.5% of surgeons continue antibiotic prophylaxis for postoperative 24 hours. Low molecular weight heparins are the most preferred anticoagulant (86%) for thromboembolism prophylaxis. While all surgeons perform primary TKA or THA, only 63.7% perform revision TKA or THA. Of the surgeons, 84.6% do not recommended antibiotic prophylaxis before dental or urologic procedures in patients who were performed TKA or THA. CONCLUSION: In Turkey, although consensus has been built on many issues regarding TKA and THA, different approaches are adopted based on academic position, duration of specialty, and employer institution.
Subject(s)
Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Operating Rooms , Postoperative Complications , Surgeons , Adult , Antibiotic Prophylaxis/statistics & numerical data , Anticoagulants/supply & distribution , Arthroplasty, Replacement, Hip/methods , Arthroplasty, Replacement, Hip/psychology , Arthroplasty, Replacement, Knee/methods , Arthroplasty, Replacement, Knee/psychology , Attitude of Health Personnel , Female , Health Care Surveys , Humans , Male , Middle Aged , Needs Assessment , Operating Rooms/organization & administration , Operating Rooms/standards , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Surgeons/psychology , Surgeons/statistics & numerical data , Surveys and Questionnaires , TurkeyABSTRACT
Canadian practice guidelines for nonvalvular atrial fibrillation (NVAF) recommend that most patients receive a novel oral anticoagulant (NOAC) in preference to warfarin to prevent stroke, but not all patients have insurance that covers NOACs. The gap between optimal therapy and drug coverage is unknown. We retrospectively assessed eligibility for NOACs in patients with NVAF at our single-centre anticoagulation clinic and ascertained whether provincial drug coverage would be in place. Most patients (89%-95%) were eligible, but only 39%-41% qualified for drug coverage. Our findings suggest most Albertans with NVAF might not have drug coverage for optimal medical therapy for stroke prevention.
Subject(s)
Anticoagulants/supply & distribution , Atrial Fibrillation/drug therapy , Clinical Audit , Eligibility Determination , Stroke/prevention & control , Administration, Oral , Alberta , Anticoagulants/administration & dosage , Follow-Up Studies , Humans , Retrospective StudiesABSTRACT
BACKGROUND: Novel oral anticoagulants are available for the management of atrial fibrillation and are considered more convenient to use than warfarin. OBJECTIVE: The main objective of this study was to describe patterns of oral anticoagulant use in the 6 months period following the availability of dabigatran at our hospital. METHODS: A cross-sectional study was conducted in a single University hospital in the province of Québec, Canada. Medical records of subjects on oral anticoagulants for atrial fibrillation that were hospitalized between October 1st, 2011 and March 31th, 2012 were reviewed. Type of use (prevalent, incident and switch) and patient's characteristics of warfarin and dabigatran users were compared using Chi-squared and T-tests. RESULTS: In the 6-month period following dabigatran availability in the hospital, 59 patients (13%) were on dabigatran and 388 (87%) on warfarin. Mean CHADS2 score, mean age and mean number of chronic medications were lower in the dabigatran group. The percentage of patients with coronary artery disease was lower and renal function was higher in the dabigatran group. CONCLUSION: Dabigatran use remained low in the first 6 months period following the approval of dabigatran at our hospital, which could be explained by limited data on the efficacy and safety of this agent in subjects with multiple comorbidities.
Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Benzimidazoles/therapeutic use , Practice Patterns, Physicians'/trends , Stroke/prevention & control , Warfarin/therapeutic use , beta-Alanine/analogs & derivatives , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Anticoagulants/supply & distribution , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Benzimidazoles/adverse effects , Benzimidazoles/supply & distribution , Cross-Sectional Studies , Dabigatran , Drug Substitution , Drug Utilization Review , Female , Hospitals, University , Humans , Male , Quebec , Retrospective Studies , Stroke/etiology , Time Factors , Treatment Outcome , Warfarin/adverse effects , Warfarin/supply & distribution , beta-Alanine/adverse effects , beta-Alanine/supply & distribution , beta-Alanine/therapeutic useSubject(s)
Anticoagulants/adverse effects , Atrial Fibrillation/drug therapy , Hemorrhage/chemically induced , Risk Assessment/methods , Stroke/prevention & control , Anticoagulants/supply & distribution , Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Drug Prescriptions/statistics & numerical data , Hemorrhage/epidemiology , Humans , Retrospective Studies , Risk Factors , Stroke/drug therapy , Stroke/epidemiology , Sweden/epidemiology , Thromboembolism/drug therapy , Thromboembolism/prevention & controlABSTRACT
Long-term anticoagulation in patients with metallic prosthetic valve disease is required according to current guidelines. We describe a patient with a functioning mitral mechanical valve without anticoagulation for 27 years. A 46-year-old man admitted to the emergency department with complains of palpitation. The patient had a mitral valve replacement because of severe mitral stenosis. He discontinued warfarin treatment 1 month after surgery because of the unavailability of this drug in Turkey. Transthoracic echocardiography revealed functioning metalic mitral valve with a mean gradient of 9 mm Hg. Fluoroscopy showed normal excursions of the mechanical mitral valve. Transesophageal echocardiography was performed and revealed fresh thrombus formation in the left atrial appendix. Admission international normalized ration (INR) level was 1.79. Due to the higher INR level and long-term survival, genetic analysis of warfarin polymorphism was performed. There was a homozygous mutation in the vitamin K epoxide reductase complex 1 (VKORC1) 1173C>T and 1639G>A genotypes. The possible explanations of long-term survival and baseline higher INR level were linked to the mutation in warfarin metabolism. We also briefly review the literature.
Subject(s)
Atrial Appendage , Heart Valve Prosthesis , Mixed Function Oxygenases/genetics , Polymorphism, Single Nucleotide , Postoperative Complications/etiology , Survivors , Thrombosis/etiology , Anticoagulants/pharmacology , Anticoagulants/supply & distribution , Anticoagulants/therapeutic use , Atrial Appendage/diagnostic imaging , Atrial Fibrillation/complications , Disease Resistance/genetics , Echocardiography, Transesophageal , Homozygote , Humans , Hydroxylation , Male , Middle Aged , Mitral Valve Stenosis/surgery , Mixed Function Oxygenases/antagonists & inhibitors , Postoperative Complications/diagnostic imaging , Postoperative Complications/prevention & control , Thrombosis/diagnostic imaging , Thrombosis/prevention & control , Turkey , Vitamin K/pharmacokinetics , Vitamin K Epoxide Reductases , Warfarin/pharmacology , Warfarin/supply & distribution , Warfarin/therapeutic useABSTRACT
The action of the coumarin-type drugs and related compounds is reviewed to their VKOR antagonistic effects. In our study, twenty 3-pyridinyl, pyrimidinyl and pyrazolyl-4-hydroxycoumarin derivatives were synthesized. A comparative in vivo (CT, PT determination) and in vitro (measurement of PIVKA-II levels) anticoagulant study with respect to warfarin showed that the synthesized compounds have different anticoagulant activities, the most prospective compounds were the 3-pyrazolyl-4-hydroxycoumarin derivatives.